Improvements in diagnostic modalities have increased the prevalence of somatotroph adenomas through the identification of active acromegaly (high IGF-1 and/or GH levels) in clinically asymptomatic patients, also called silent somatotroph adenomas [3]. This evidence concerns the gene GH1 and acromegaly.